Skip to NavigationSkip to content

plaque psoriasis

New Phase 3 data confirms safety and efficacy of UCB's Cimzia in plaque and psoriatic arthritis

New Phase 3 data has been released by UCB Pharma on the safety of Cimzia (certolizumab pegol) in the treatment of moderate-to-severe plaque psoriasis, and its efficacy in patients showing signs of psoriasis-related nail disease and those showed an inadequate early treatment response to the drug.

The first 96 weeks of data derived from 995 participants across two ongoing Phase 3 studies demonstrated that “confirmed the long-term safety of Cimzia in the treatment of psoriasis”, with no new safety concerns flagged, while the overall incidence of adverse events was low.

NICE recommends UCB's Cimzia in severe plaque psoriasis

NICE has announced its decision to recommend UCB Pharma’s Cimzia (certolizumab pegol) for use on the NHS in England in the treatment of severe plaque psoriasis in patients who have failed to respond to, or are unsuitable for, other systemic treatments.

The judgement also adds an additional treatment option for women before or during pregnancy, as well as while breastfeeding.

Janssen's Tremfya maintains skin clearance after 3 years in plaque psoriasis

Janssen has revealed new long-term data for its IL-23 inhibitor Tremfya (guselkumab) in moderate to severe plaque psoriasis, demonstrating skin clearance which was maintained after three years of treatment.

Presented at the 37th Fall Clinical Dermatology Conference in Las Vegas, the data showed that 82.8% of Tremfya patients achieved and maintained a score of 90 on the Psoriasis Area Severity Index, representing a 90% improvement in skin clearance, while 96.4% of patients scored at least PASI 75.

Janssen's Tremfya shows long-term efficacy in moderate to severe plaque psoriasis

Janssen has unveiled new Phase 3 trial data for its IL-23 inhibitor Tremfya (guselkumab), demonstrating that the drug was able to generate high skin clearance rates in patients with moderate to severe plaque psoriasis when administered as a long-term treatment.

NICE recommends plaque psoriasis contender for NHS use

The use of Almirall’s psoriasis drug Skilarence (dimethyl fumarate) on the UK’s NHS is one step closer after NICE gave draft guidance recommending its use in moderate to severe plaque forms of the disease in adult patients for whom other systemic non-biological treatments are not applicable.

The institute based its decision on trial data which indicated that Skilarence was effective at improving the condition compared to placebo. However, it failed to prove as effective as existing systemic biological therapies, as well as Celgene’s drug Otzela (apremilast).

FDA approves Lilly's plaque psoriasis drug Taltz

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Taltz (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Taltz, administered via injection, is designed to specifically target IL-17A, a protein that plays a role in driving underlying inflammation in psoriasis.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches